Pediatric lymphomas/leukemias

Table XXXni Pediatric Lymphomas/Leukemias. Network of Chaotic Mutations Major Errors in the System Repeated Recognizable Patterns for the EstabUshment of Immoitalized Chemo-Radiation-Resistant Transformed Cells ...

Riopel M, Dickman PS, Link MP, et al. MIC2 analysis in pediatric lymphomas and leukemias. Hum Pathol. 1994 25(4) 396-399. 

In addition, pediatric testing of anticancer agents is necessitated by childhood prevalence of fast growing cancers, such as lymphomas, leukemias, and... 

Vincristine has been effectively combined with prednisone for remission induction in acute lymphoblastic leukemia in children. It is also active in various hematologicmalignancies such as Hodgkin s and non-Hodgkin s lymphomas, and multiple myeloma, and in several pediatric tumors including rhabdomyosarcoma, neuroblastoma, Ewing s sarcoma, and Wilms tumor. 

Soussain, C., Patte, C., Ostronoff, M., Delmer, A., Rigal-Huguet, F., Cambier, N., Leprise, P. Y., Francois, S., Cony-Makhoul, P., Harousseau, J. L., et al., Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85, 664-674 (1995). 

Vincristine is part of many chemotherapeutic regimens, based on its lack of myelosuppressive toxicity. It is used, for example, in the treatment of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), lymphomas, neuroblastoma, brain tumors, and Wilms tumor. The generally recommended dose in adults is 1.4 mg/m /week intravenously (5). Some clinicians have recommended an absolute upper limit of 2 mg, but this limitation is still a matter of debate (6). The usual pediatric dosage is 1.5-2 mg/m, but for children weighing 10 kg or less or who have a body surface area less than 1 m, the manufacturers recommend that treatment should be begun at 0.05 mg/kg once a week (5). 

Lindstrom, F. D., Williams, R. C., and Theologides, A., Urinary light chain excretion in leukemia and lymphoma. Clin. Exp. Immunol. 6, 83-90 (1969). Lipsey, A. I., Kahn, M. J., and Bolande, R. P., Pathologic variants of congenital hypogammaglobulinemia an analysis of 3 patients dying of measles. Pediatrics 39, 659-674 (1967). 

Rasbnricase is an antimetabolite that catalyzes enzymatic oxidation of nric acid into an inactive and soluble metabolite (allantoin). It is indicated in initial management of plasma nric acid levels in pediatric patients with leukemia, lymphoma, and solid tnmor malignancies who are receiving anticancer therapy expected to result in tumor lysis and snbsequent elevation of plasma uric acid. 

Vincristine is a standard component of regimens for treating pediatric leukemias, lymphomas, and solid tumors. In large-cell non-Hodgkin s lymphomas, vincristine remains an important drug. 

Pediatric acute lymphocytic leukemia, osteogenic sarcoma, Burkitts lymphoma, non-Hodgkin s lymphoma, breast, head, neck, small cell lung, choriocarcinoma, psoriasis, rheumatoid arthritis. 

Anthracyclines are known potent antitumor drugs used worldwide for the treat ment of a wide variety of neoplasias. Daonorubicin is approved by the U.S. Food and Drug Administration (FDA) for treatment of acute nonlymphocytic leukemia (adults) and acute lymphatic leukemia (adults and pediatric). Daunorubicin also may be effective against chronic myelogenous leukemia, Ewing s sarcoma, neuroblastoma, non-Hodgkin s lymphoma, and Wilms s tumor (113). 

Nickel RS, Keller F, Bergsagel J, Cooper T, Daves M, Sabnis H, et al. Mitoxantrone as a substitute for daunorubidn during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Pediatr Blood Cancer 2014 61(5) 810-4. 

---